OphthalmologyNews.net

Ophthalmology Xagena

Search results for "Eylea"

Results for VEGF Trap-Eye ( Aflibercept ophthalmic solution ) from the Phase 3 MYRROR study in myopic choroidal neovascularization ( mCNV ) were presented. Patients receiving VEGF Trap-Eye at a dose o ...


Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ...


Regeneron has announced that detailed one-year results from the VIEW 1 and VIEW 2 phase 3 studies of Aflibercept ( Eylea ) injection, published in the journal Ophthalmology. Eylea, for the treatmen ...


The FDA ( Food and Drug Administration ) has accepted for priority review the supplemental biologics license application ( sBLA ) for Eylea ( Aflibercept ) injection for the treatment of diabetic reti ...


In September 2014, the FDA ( Food and Drug Administration ) granted Eylea ( Aflibercept ) injection Breakthrough Therapy designation for the treatment of diabetic retinopathy in patients with diabetic ...


Eylea ( Aflibercept ) injection has been recommended for approval by the European Committee for Medicinal Products for Human Use ( CHMP ) for the treatment of visual impairment due to macular edema s ...


A single-practice retrospective chart review has reported on long-term visual outcomes in patients receiving continuous fixed-interval dosing of anti-vascular endothelial growth factor ( VEGF ) treatm ...